Today 4D Pharma has released encouraging preliminary safety and clinical observation data from its Phase I/II study of MRx0518 in combination with Keytruda® in patients with advanced and progressive malignancies. Initial data shows the therapy combination was well-tolerated producing no drug-related serious adverse events, and that early clinical observations show that two patients demonstrated a partial response and a third patient presented stable disease - a significant feature given the adva ....
06 Nov 2019
Encouraging preliminary Phase I/II data in first of kind oncology study
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Encouraging preliminary Phase I/II data in first of kind oncology study
- Published:
06 Nov 2019 -
Author:
Edward Thomason -
Pages:
3
Today 4D Pharma has released encouraging preliminary safety and clinical observation data from its Phase I/II study of MRx0518 in combination with Keytruda® in patients with advanced and progressive malignancies. Initial data shows the therapy combination was well-tolerated producing no drug-related serious adverse events, and that early clinical observations show that two patients demonstrated a partial response and a third patient presented stable disease - a significant feature given the adva ....